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温度応答型生分解性スマートバイオマテリアルのゲル化機序の解明と 
薬物放出デバイスとしての利用に関する研究 
 
≪概要≫ 
ある種のポリマー水溶液は，温度等の外部刺激に応答してゾル状態からゲル状態へと転移するこ
とが知られている。これらのうち，室温 (生体外) ではゾル，体温付近 (生体内) ではゲルとなる
生分解性のポリマーは，注射による投与が可能であり，Injectable Polymer (IP)としての利用が検討
されている。生分解性 IPは，投与後は注入部位に留まり，役割を果たした後には生体内で分解し
て代謝されるため，低侵襲な組織再生用足場材料や薬物徐放デバイスとしての応用が期待されて
いる。その代表例として，疎水性セグメント (A) に乳酸-グリコール酸共重合体 (PLGA) ，親水
性セグメント (B) にポリエチレングリコール (PEG) を有する ABA 型トリブロック共重合体 
(PLGA-b-PEG-b-PLGA) などの脂肪族ポリエステルと PEG とのブロック共重合体が知られている。
このような IPについては，既に数多くの研究成果が報告されており，臨床応用への期待も高まっ
てきているが，解決すべき幾つかの課題が残っている。 
論文提出者の所属する研究室では，疎水性セグメントにカプロラクトン-グリコール酸共重合体 
(PCGA) を用いることで，凍結乾燥による粉末化を可能とし，さらに PEGを添加することにより，
凍結乾燥後の粉末試料から注射用分散製剤を調製する時間を著しく短縮することを見出し，臨床
現場において即時調製可能な温度応答型ポリマー溶液の開発に成功した。また，温度に応答して
ゲル化を起こす際に，共有結合を形成し，体液等で高度に湿潤した環境下においても長時間ゲル
状態を維持することができる IP製剤の開発にも成功している。 
このような温度に応答して共有結合ゲルを形成するブロック共重合体システムでは，低温におけ
る架橋反応の生起を抑えつつ，温度上昇に伴ってゲル化が起こる時にのみに架橋反応を進行させ
る必要があり，ミセル状に溶解したポリマーの交換反応の抑制が鍵となる。しかしながら，ミセ
ル様の溶解状態におけるポリマー鎖交換反応やその温度依存性に関する知見は未だ十分には得ら
れておらず，さらに機能を高めた IP製剤を合理的に設計・開発するためには，そのメカニズム解
析が重要である。また，開発した共有結合形成 IP システムが，非共有結合型 IP システムと比較
して，低分子および高分子薬物の徐放化にもたらす効果についてはまだ検討されていない。 
そこで本論文では，PCGA-b-PEG-b-PCGAポリマーを基軸としたポリマー群を用いて，ミセル状
態でのポリマーの交換過程を含むゲル化メカニズムの解明と，実際の薬物徐放デバイスとしての
応用を意図したペプチド性薬物の徐放化に関して検討を加えた。 
 
 
本論文は，4つの Chapterから構成される。以下，本論文の内容を Chapterごとに要約する。 
 
≪Chapter 1≫ 
Chapter 1では，徐放性注射製剤の概要を紹介するとともに，温度応答型生分解性 IPの課題や望
まれる諸特性を示し，本研究の目的について述べる。 
 
≪Chapter 2≫ 
Chapter 2 では，温度応答型生分解性 ABA 型トリブロック共重合体がゾル-ゲル転移するメカニ
ズムの解析を検討した結果について述べる。ABA型トリブロック共重合体は水溶液中でフラワー
ミセルを形成することが知られているが，フラワーミセルを形成するミセル間のポリマー鎖交換
については議論されていない。そこで本研究では，蛍光共鳴エネルギー移動  (Fluorescence 
Resonance Energy Transfer, FRET) 現象を利用し，ミセルを形成するポリマー鎖の交換状態から
PCGA-b-PEG-b-PCGAのゲル化過程を考察した。FRETが起こる蛍光物質の組み合わせとして，ナ
フタレンとダンシルを選択し，各蛍光物質を PCGA-b-PEG-b-PCGA の末端ヒドロキシル基 
(tri-PCG) に修飾した。ナフタレンを修飾した tri-PCG-nap のミセル溶液およびダンシルを修飾し
た tri-PCG-danのミセル溶液を各々調製し，混合後，温度を上昇させることにより FRETが起こる
ことを確認した。さらにゲル化するポリマー濃度にて，各温度で 1分後の FRET の挙動を確認し
たところ，ゲル化温度の前後で立ち上がりが認められるシグモイド様曲線を描くことが判明した。
しかし，ゲル化する前からミセルを形成するポリマー鎖の交換が起こることも明らかとなった。
ゲル化する前からミセル間においてポリマー鎖の交換が起こることは，共有結合ゲルを形成する
ブロック共重合体システムでは不利である。事実，共有結合ゲルを形成するブロック共重合体シ
ステムでは，室温下 3 時間程度でゲル化する現象が認められた。一方，凍結乾燥から得られた温
度応答型生分解性ポリマーの粉末を PBS で分散した溶液では，室温下 24 時間経過した場合もゲ
ル化は認められなかった。そこで，FRET によるポリマー鎖の交換を調査したところ，溶液に比
べ，ポリマー鎖の交換が抑えられていることを明らかにした。以上より，温度応答型生分解性 ABA
型ブロック共重合体が形成するミセルは，ポリマー鎖の交換が起こっていること，凍結乾燥粉末
の分散液ではポリマー鎖の交換を押えることが出来ることを明らかとし，今後の温度応答型生分
解性ポリマーの設計に役立つと考える 1)。 
 
≪Chapter 3≫ 
Chapter 3 では，薬物徐放デバイスとしての応用にむけた検討結果について述べる。論文提出者
の所属する研究室において，tri-PCG の末端のヒドロキシル基にアクリロイル基を修飾した
tri-PCG-Acryl 水 溶 液 と ， 水 に 不 溶 な ポ リ チ オ ー ル で あ る Dipentaerythritolhexakis 
(3-mercaptopropionate) (DPMP) を内包した tri-PCGミセル水溶液を混合したシステムは，温度上昇
に伴ってゲル化が起こる際に共有結合を形成することにより，tri-PCG単独に比べ，ゲル状態にお
ける力学強度の向上および生体内でのゲル状態の維持期間を長くすることに成功している。さら
に tri-PCG-Acrylと DPMPの含有率を変化させることで，ゲル状態の維持期間を自在に調整できる
ことを明らかにしている。この系を，高分子および低分子の薬物を徐放する製剤として利用した
 
 
場合には，共有結合の形成によるゲル状態の長期間維持効果により，これまでの IP製剤と比較し
て，長期間の薬物徐放が達成されることが期待できる。そこで本研究では，tri-PCG-Acryl 及び
DPMP内包 tri-PCGシステムにおいて，GLP-1を薬物モデルペプチドとして選択し，その製剤作成
と薬物放出挙動について in vitro及び in vivoにおいて検討した。結果，従来の温度応答性ポリマー
に比べ，tri-PCG-Acrylと DPMPの含有率が高い温度応答性ポリマー，すなわち，ゲルの維持期間
が長い製剤の方が，GLP-1 の血中維持期間が長いことが分かった。このことから，後期における
薬物放出は，ゲルの崩壊と共に薬物が放出されていると考えられた 2)。 
 
≪Chapter 4≫ 
 Chapter 4では，本研究で得られた知見や成果についてその内容を総括し，温度応答型生分解性
スマートバイオマテリアル分野に対する本研究の貢献とその意義を述べる。 
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General Introduction  
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1.1  Parenteral depot formulation 
   There are various parenteral dosage forms, such as solutions, suspensions, emulsions, liposomes, 
micelles, implants and microspheres. However, long-term (over 1 month) sustained release formulations 
are limited to suspensions1-3, implatns4,5, and microspheres6,7. These formulations are deposited at the 
subcutaneous or intramuscular and gradually release their drug. Parenteral depot formulations have the 
potential to avoid the need for constant infusion of the drug or a very high frequency of injections, 
thereby enhancing patient compliance. Furthermore, depot formulations can minimize undesirable side 
effects caused by fluctuating drug blood levels typical of immediate release products, and formulations 
with various drug release duration times have been developed. 
   Parenteral depot formulations for hydrophilic compounds are limited to implants and microspheres. 
Implants allow the longest duration drug release of all parenteral depot formulations (e.g., one year)4. 
However, subcutaneous implants require use of a large needle gauge or surgery (e.g., Zoladex®), causing 
patient anxiety and discomfort. In contrast, microspheres are administrated using a smaller needle gauge, 
causing less stress to the patient. However, the disadvantages of microspheres are high manufacturing 
cost, a difficult administration procedure, and a danger of incomplete dispersion and syringe clogging8,9. 
Given the drawbacks of implants and microspheres, there has been significant effort to develop 
alternative depot systems with the following characteristics: 
1) Painless and easy administration through small needle gauges 
2) Easy to manufacture at low cost 
 
1.2  In situ forming implant 
   Some formulations are a low-viscosity liquid prior to injection and solidify into a semi-solid or 
solid depot at the injection site after administration. These drug-loaded formulations can be injected 
using a small-gauge needle and the drug is released gradually from the depot at the injection site. 
Formulations with such properties are typically known as in situ forming implant (ISFI) systems. ISFI 
systems are expected to be less invasive and less painful than implant or microsphere depots, and many 
injectable and biodegradable ISFI systems have been developed. ISFIs are classified according to their 
mechanism of implant formation8-11. 
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(1) In situ polymer precipitation 
(2) Thermoplastic pastes 
(3) In situ cross-linked systems 
   (3-1) Chemically cross-linked injectable polymer systems 
   (3-2) Physically cross-linked injectable polymer systems 
 
1.2.1  In situ polymer precipitation 
   An in situ polymer precipitation system was proposed by Dunn et al.12 and formed the basis of 
ISFI systems. A water-insoluble and biodegradable polymer is dissolved in an organic solvent, and the a 
drug is mixed in. When this formulation is injected into the body, the organic solvent diffuses and water 
penetrates into the organic phase. This leads to phase separation and precipitation of the polymer, 
forming a depot at the injection site. ATRIX Laboratories developed a technology called Atrigel® based 
on this method13,14. The most advanced product using Atrigel® technology, Eligard®, contains the 
luteinizing hormone-releasing hormone (LHRH) agonist leuprolide acetate and 
poly(DL-lactide-co-glycolide: 50/50, 75/25 and 85/15) (PLGA) dissolved in N-methyl-2-pyrrolidone 
(NMP). Eligard® is achieved to maintain the serum level of testosterone for 6 months with safety and 
efficacy. However, the NMP solvent has raised concerns with respect to biocompatobolity15. 
 
1.2.2  Thermoplastic pastes 
   Thermoplastic pastes are based on polymers with a melting point or glass transition temperature in 
the range of 25 °C to 65 °C. These polymers are heated above their melting point or glass transition to a 
liquid state before injection. After administration, they cool to body temperature and form a semi-solid 
depot in the body. Drugs are mixed with the molten polymer without the use of organic solvents. A 
semi-solid poly(ortho esters) (POE) was developed by Heller et al. as a biodegradable material16. Four 
generations of POEs have been developed, starting in the 1970s. The third- and fourth-generation POEs 
are highly biocompatible, and the fourth-generation POE can be manufactured reproducibility. These 
POEs are in a semi-solid state at room temperature (r.t.), allowing therapeutic agents to be mixed in 
without heating or the use of solvents. However, POEs cannot be injected through a small-gauge needle: 
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for example, third-generation POEs cannnot be easily injected through a 20-gauge needle17. 
 
1.2.3  In situ cross-linked systems 
   There are two types of in situ cross-linked systems: covalently (chemically) crosslinked systems 
and non-covalently (physically) cross-linked systems. 
 
1.2.3.1  Chemically cross-linked systems 
   Chemically cross-linked systems can be categorized into two groups: radical polymerization 
systems (including photopolymerization) and chemical reaction systems. 
   In general, radical polymerization systems require two materials: polymers containing 
double-bonds and a free radical initiator. However, cross-linking agents used for free radical initiation 
are typically toxic18,19. In contrast, ultraviolet (UV) or visible light are required for photopolymerization 
and photosensitive initiators (e.g., eosin dyes) are less toxic than free radical initiators. Consequently, 
photopolymerization systems hold promise for various biomedical applications20. Although the use of in 
situ gels formed by UV irradiation is mainly limited to dental applications, photopolymerization systems 
can be also used for minimally invasive surgery attendant therapies such as peritumoral injection after 
surgery by using catheters or laproscopic devices, allowing direct exposure of the formulations to UV 
light9. 
   Chemical reactions such as amine-succinimide reaction21, Michael-type addition, disulfide 
formation, Diels-Alder reaction, azide-alkyne cycloaddition22, Schiff base formation between an amine 
and aldehyde23 were reported as in situ gelation systems. In such systems, two water-soluble polymers 
with different functional groups (OH, SH, COOH, NH2) are separately dissolved in aqueous solution, 
and then mixed to allow the functional groups to react before injection. A solid (gel) state is formed from 
the liquid (sol) state by the formation of a covalent cross-linked network in the body. For example, 
Michael-type 1,4-addition occurs upon nucleophile attack on the β position of an α,β-unsaturated 
carbonyl compound. Thiols, alcohols and amines are often used as the nucleophile. Thiol groups are 
suitable for use in cross-linking biomaterial hydrogels because the thiol groups have a lower pKa (about 
8.0) and stronger nucleophilicity than amine and hydroxyl groups, respectively. Therefore, this reaction 
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is highly selective even under physiological conditions (37 °C, pH = 7.4). Michael-type addition between 
thiol and maleimde24, acryloyl25 and vinyl sulfone groups26 has been reported for biomaterial 
applications, but it is generally difficult to control the gelation time. 
 
1.2.3.2  Physically cross-linked systems 
   Physical cross-linking between polymers is due to hydrophobic interactions27, ionic interactions28, 
or stereocomplex formation29 triggered by external stimuli under physiological temperature, pH and 
ionic length. Temperature-responsive polymers can be especially attractive for use in ISFI system as they 
do not require organic solvents, copolymerization agents, or externally applied triggers9. Such polymer 
solutions with a sol-to-gel transition point between r.t. and body temperature have been extensively 
investigated as injectable polymer (IP) systems. An aqueous solution of a polymer is in the sol state at r.t. 
and thus water-soluble bioactive reagents such as proteins, peptides or living cells can be mixed and 
easily injected into the body to form a hydrogel at the desired site. Furthermore, biodegradable IP 
systems are more likely to be applied clinically as implantable materials compared to non-biodegradable 
IPs such as poly(N-isopropyl acrylamide)30 and triblock poly(ethylene oxide)-poly(propylene 
oxide)-poly(ethylene oxide)31 because they can be excreted from the body after completing their 
function. 
   Such biodegradable thermo-gelling polymer systems have the advantage of rapid gelation in 
response to a temperature increase, although several issues remain regarding previously reported 
biodegradable IP systems intended for clinical application32,33. For example, once the hydrogel is formed 
in the body, it is likely to quickly revert to the sol state (typically in less than 24 h) in the presence of a 
large amount of water or body fluid, such as in the intraperitoneal space or the interior of a blood vessel. 
This reversion is due to gelation being dependent on non-covalent (hydrophobic) interactions, and gel 
formation is an equilibrium process controlled by the conditions, such as temperature and concentration 
of the gel. This may cause the hydrogel to disintegrate before it can perform its function, or the rapid 
release of bioactive agents. 
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1.3  Next-generation temperature-responsive biodegradable IP systems 
   Ohya et al. recently reported biodegradable temperature-triggered covalent gelation systems 
exhibiting longer and controllable duration times of the gel state by a "mixing strategy"32,34. They 
synthesized a tri-block copolymer of poly(ε-caprolactone-co-glycolide) (PCGA) and poly(ethylene 
glycol) (PEG), PCGA-b-PEG-b-PCGA (tri-PCG), by attaching acryloyl groups on both termini 
(tri-PCG-Acryl). A mixture of tri-PCG-Acryl micelle solution and tri-PCG micelle solution containing 
hydrophobic hexa-functional polythiols exhibited an irreversible sol-to-gel transition by covalent 
cross-linking in response to a temperature increase, and a longer and controllable duration of the gel 
state34. The acryloyl groups of tri-PCG-Acryl in the micelle did not react with the polythiol molecules 
immediately after mixing because the polythiols are present in separate micelle cores. However, upon 
inter-micellar aggregation during the sol-to-gel transition, covalent cross-linking occurs by thiol-ene 
reaction of acryloyl groups of tri-PCG-Acryl with the polythiol molecules. 
 
1.4  Overview of this work 
   In this work, I attempt to understand the sol-to-gel transition behavior of temperature-responsive 
injectable polymer systems and apply these biodegradable temperature-triggered covalent gelation 
systems to drug release device. This thesis contains the following two chapters. 
    
   In Chapter 2, I investigated polymer chain transfer (exchange) between micelles composed of 
temperature-responsive biodegradable polymer during the gelling process. Amphiphilic triblock 
copolymers of PEG and aliphatic polyesters such as PCGA are typical examples of thermo-gelling 
polymers. The gelation mechanism of these polymers comprises two important steps: polymer chain 
transfer between the micelles, and subsequent aggregation of the polymer micelles. We previously 
reported an IP system exhibiting a temperature-responsive irreversible sol-gel transition that formed a 
covalently cross-linked hydrogel34. An IP formulation prepared by the "freeze-dry with PEG/dispersion" 
method (D-sample) retained its sol state at r.t. longer than a formulation prepared by the usual dissolution 
method (S-sample)35. I hypothesized that polymer chain transfer between micelles was suppressed in the 
D-samples because the micelle cores were in a solid-like semi-crystalline state. In this study, I 
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investigated polymer chain transfer using a fluorescence resonance energy transfer (FRET) method to 
reveal the role of polymer chain transfer in the sol-to-gel transition. I synthesized a triblock copolymer of 
PCGA and PEG (tri-PCG) with covalently attached naphthalene or dansyl groups at both termini, 
generating tri-PCG-nap and tri-PCG-dan for use as a FRET donor and acceptor, respectively. 
Investigation of the FRET behavior of a mixture of tri-PCG-nap/tri-PCG micelles and 
tri-PCG-dan/tri-PCG micelles revealed that polymer chain transfer between micelles was strongly 
accelerated at the gelation temperature, and polymer chain transfer in D-samples was suppressed 
compared to S-samples. 
 
 
Figure 1. Illustration showing the experiments described in Chapter 2. 
 
   In chapter 3, I investigated the release behavior of glucagon-like peptide-1 (GLP-1) from a 
biodegradable injectable polymer (IP) hydrogel. This hydrogel shows temperature-responsive 
irreversible gelation due to covalent bonds formation through a thiol-ene reaction. In vitro sustained 
release of GLP-1 from an irreversible IP formulation was observed compared with a reversible (physical 
gelation) IP formulation. Moreover, pharmaceutically active levels of GLP-1 were maintained in blood 
after subcutaneous injection of the irreversible IP formulation into rats. This system holds promise the 
minimally invasive sustained release of peptide drugs and other water-soluble bioactive reagents. 
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Figure 2. Illustration showing the experiments described in Chapter 3. 
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Analysis of the sol-to-gel transition behavior of 
temperature-responsive injectable polymer 
systems by fluorescence resonance energy 
transfer 
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2.1  Introduction 
   Some types of polymer solutions exhibit sol-to-gel transitions in response to a temperature 
increase. Thermo-gelling polymer systems having sol-to-gel transition points between room temperature 
(r.t.) and body temperature have been extensively investigated as injectable polymer (IP) systems for 
biomedical applications. An aqueous solution of such a polymer is in the sol state at r.t. and can easily be 
injected into the body to form a hydrogel at the desired site. Biodegradable IP systems are expected to be 
applied clinically as implantable materials, because they can be excreted from the body after their 
expected roles are completed. Water-soluble bioactive reagents, such as proteins and peptides or living 
cells, can be mixed with the polymer solutions and injected at a desired site to form a hydrogel. 
Therefore, such biodegradable IP systems have been investigated for adapting to minimally invasive 
drug delivery systems (DDS) exhibiting sustained release of drugs1,2, biodegradable scaffolds in 
regenerative medicine3,4, materials for adhesion prevention after surgical operations5,6, embolization 
treatments of blood vessels7, and endoscopic submucosal dissection (ESD) materials8. Amphiphilic block 
copolymers of poly(ethylene glycol) (PEG) as hydrophilic segments and biodegradable aliphatic 
polyesters as hydrophobic segments are known as typical examples of biodegradable IPs. For example, 
ABA triblock copolymers using poly(D,L-lactide) (PDLLA)9, poly(D,L-lactide-co-glycolide) 
(PLGA)10,11, poly(ε-caprolactone) (PCL)12,13, and poly(ε-caprolactone-co-glycolide) (PCGA)14-16 as 
hydrophobic segments have been reported. 
   Such biodegradable thermo-gelling polymer systems have an advantage of rapid gelation in 
response to a temperature increase, however there have been some issues in previously reported 
biodegradable IP systems for clinical applications. The hydrogel once formed in the body is likely to 
revert to the sol state in a short period (typically less than 24 h) in the presence of a large amount of 
water or body fluid, such as in the intraperitoneal space or the interior of a blood vessel, because the 
gelation is caused by non-covalent (hydrophobic) interactions, and gel formation is an equilibrium 
process controlled by the surrounding conditions such as temperature and concentration. This may cause 
the disappearance of the hydrogel before it can perform its role or the rapid release of bioactive agents. 
Another problem is with the preparative processes for IP formulations. Most biodegradable IPs are sticky 
pastes in the dry state at r.t., and it takes a long time to dissolve them in aqueous solution. These 
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characteristics are inconvenient in clinical settings and are obstacles for clinical applications of IP 
systems. 
   To solve these two problems, we recently reported biodegradable temperature-triggered covalent 
gelation systems exhibiting longer and controllable duration times of the gel state by a "mixing 
strategy"17,18. We synthesized a tri-block copolymer of PCGA and PEG, PCGA-b-PEG-b-PCGA 
(tri-PCG), attaching acryloyl groups on both termini (tri-PCG-Acryl). A mixture of tri-PCG-Acryl 
micelle solution and tri-PCG micelle solution containing hydrophobic hexa-functional polythiols 
exhibited an irreversible sol-to-gel transition by covalent cross-linking in response to a temperature 
increase, and exhibited a longer and controllable duration time for the gel state18. Just after mixing, the 
acryl groups of tri-PCG-Acryl in the micelle did not react with polythiol molecules because they existed 
in other micelle cores. Upon inter-micellar aggregation during the sol-to-gel transition, covalent 
cross-linking by the thiol-ene reaction of acryl groups of tri-PCG-Acryl with polythiol molecules 
occurred. Moreover, we applied the "freeze-dry with PEG/dispersion" method19 as a quick 
extemporaneous preparation method developed in our previous studies on this system. We found that the 
IP formulations prepared by the "freeze-dry with PEG/dispersion" method (D-samples) retained their sol 
state at r.t. after preparation longer (more than 24 h) than formulations prepared by the usual heating 
dissolution method (S-samples), which undergo gelation typically within 3 h after preparation20. One of 
the differences between D-samples and S-samples is the state of the cores (solid-like or not). We 
confirmed that the micelle core of D-samples was in a solid-like semi-crystalline state. We hypothesized 
that gradual gelation in S-samples at r.t. was caused by transfer of tri-PCG-Acryl molecules from 
tri-PCG-Acryl micelles to tri-PCG micelles containing polythiols, and such polymer chain transfer was 
suppressed in D-samples. The polymer chain transfer rate for D-samples must be much slower than that 
for S-samples, because the micelle cores in D-samples were in a solid-like semi-crystalline state. 
   In this study, to confirm the hypothesis described above, we investigated the rate of polymer chain 
transfer (exchange) between micelles in the thermo-gelling polymer (tri-PCG) system. The previously 
proposed mechanism for sol-to-gel transition of biodegradable thermo-gelling polymer systems was a 
temperature-triggered micellar aggregation by dehydration of the PEG chain surrounding the micelles 
and subsequent growth of fibrous networks of the aggregation17,21-24. However, the polymer transfer 
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(exchange) behavior during the sol-to-gel transition has not been well investigated. Thus, we explore the 
effects of polymer transfer among micelles on the sol-to-gel transition, and reveal the primary factor for 
the stability of the D-sample. 
   To investigate polymer chain transfer in polymeric micelle systems, several methods have 
previously been reported, such as size exclusion chromatography (SEC)25, fluorescence 
measurements26-28, sedimentation29, and small-angle neutron scattering30. In this study, we selected the 
fluorescence resonance energy transfer (FRET) method to investigate polymer chain exchange and 
transfer, because we can obtain real-time information using FRET for the polymer molecule transfer 
among the micelles in solution at various temperatures. 
   We employed naphthalene (nap) and dansyl (dan) groups as donors and acceptors, respectively, 
considering their overlapping fluorescence and absorption spectra31 and relatively small molecular sizes. 
These fluorescence groups were covalently attached to both termini of tri-PCG to give tri-PCG-nap and 
tri-PCG-dan. The obtained tri-PCG-nap and tri-PCG-dan were mixed separately with tri-PCG to prepare 
tri-PCG/tri-PCG-nap micelle solution and tri-PCG/tri-PCG-dan micelle solution. After mixing the two 
micelle solutions, the fluorescence spectra of the mixed solution under various conditions were measured 
to evaluate polymer chain transfer (Figure 1). 
 
Figure 1. Schematic illustration for the polymer chain transfers in the tri-PCG micelle systems and the 
analysis by FRET. 
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2.2  Experimental procedure 
2.2.1  Materials 
   PEG (molecular weight (MW) = 1,500 Da; PEG1500), ε-caprolactone (CL), tin 2-ethylhexanoate 
(Sn(Oct)2), N,N'-dicyclohexylcarbodiimide (DCC), and dimethylaminopyridine (DMAP) were purchased 
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). PEG (MW = 2,000 Da; PEG2000) and 
glycolide (GL) were purchased from Sigma-Aldrich (St Louis, MO, USA). Dansyl glycine and 
1-naphthoic acid were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Water was 
purified by a Milli-Q (Merck-Millipore, Darmstadt, Germany) system. All other reagents and organic 
solvents were commercial grade and used without further purification. 
 
2.2.2  Measurements 
   1H nuclear magnetic resonance (1H-NMR) spectra were recorded on a nuclear magnetic resonance 
spectrometer (400 MHz, JNM-GSX-400, JEOL) using deuterated solvent (CDCl3). The chemical shifts 
were calibrated against tetramethylsilane (TMS) and/or solvent signal. The number-average molecular 
weights (Mn) were calculated from 1H-NMR spectra. The weight-average molecular weights (Mw) and 
the polydispersity indexes (Mw/Mn) of the polymers were determined by size exclusion chromatography 
(SEC) (column: TSKgel Multipore HXL-M × 2; detector: RI). The measurements were performed using 
dimethylformamide (DMF) as an eluent at a flow rate of 1.0 mL min-1 at 40 °C using a series of PEG as 
standards. The fluorescence spectra were recorded by a FP-8300 (JASCO, Tokyo, Japan) 
spectrofluorometer at 25 °C. The excitation wavelength was 290 nm with excitation and emission 
bandwidths of 5 nm. The spectra were recorded from 300 to 600 nm with a scan rate of 1000 nm min-1. 
Thermal analysis of the sample solutions was conducted using a differential scanning calorimeter 
(DSC-60, Shimadzu, Kyoto, Japan) with sealed aluminum pans. 
 
2.2.3  Synthesis of tri-PCG-dan and tri-PCG-nap 
   PCGA-b-PEG-b-PCGA triblock copolymers (tri-PCG) were synthesized by ring-opening 
copolymerization of CL and GL in the presence of PEG1500 as a macroinitiator and Sn(Oct)2 as a catalyst 
according to the method reported previously19 (Scheme 1). Briefly, PEG1500 (16.7 g, 11.16 mmol) in a 
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100-mL flask with a stopcock was dried under vacuum at 120 ºC for 5 h. After cooling to r.t., CL (37.0 g, 
324.5 mmol), GL (6.49 g, 55.9 mmol) (molar ratio of CL to GL (CL/GL) was 5.8) and Sn(Oct)2 (159.9 
mg, 394.7 μmol) were added to the flask which was then dried under vacuum at r.t. for 12 h. 
Polymerization was carried out at 160 ºC for 12 h by soaking the flask in an oil bath. The product was 
purified by reprecipitation using chloroform (100 mL) as a good solvent and diethyl ether (1000 mL) as a 
poor solvent to give a white solid of tri-PCG. 
   Tri-PCG-dan and tri-PCG-nap were synthesized through coupling reactions of terminal hydroxyl 
groups of tri-PCG with the carboxyl groups of dansyl glycine or 1-naphthoic acid (Scheme 2). Dansyl 
glycine (2.3 g, 7.47 mmol) was dissolved in DMF (7 mL). DCC (1.9 g, 8.98 mmol) was also dissolved in 
DMF (5 mL). These solutions were mixed and stirred at 4 ºC for 1 h. The obtained solution was added to 
the solution of tri-PCG (5.0 g, 0.94 mmol) and DMAP (63.1 mg, 0.75 µmol) in DMF (15 mL). The 
mixture was then stirred for 48 h at r.t. Dicyclohexylurea produced as a byproduct was removed by 
filtration, and the filtrate was evaporated under reduced pressure to remove DMF. The obtained products 
were purified by reprecipitation using chloroform as a good solvent and a mixture of diethyl ether and 
methanol (4/1, v/v) as a poor solvent. The reprecipitation procedure was repeated several times until no 
low-molecular-weight compound was detected. The resulting precipitate was washed with a cooled 
mixture of diethyl ether and methanol (4/1, v/v), and dried under vacuum overnight to give tri-PCG-dan. 
Similar procedures were carried out using 1-naphthoic acid instead of dansyl glycine to give 
tri-PCG-nap. 
 
2.2.4  Sol-to-gel transition of tri-PCG and mixture 
   The sol-to-gel transition behavior of tri-PCG and the mixtures was investigated by a test-tube 
inverting method17 as follows. A vial containing a micelle solution was immersed in a water bath at the 
desired temperature for 15 min, removed from the water bath, then inverted repeatedly to determine sol 
state or gel state based on the criteria of ‘‘flow’’ (= sol) and ‘‘no flow’’ (= gel) in 30 sec, with a 
temperature increment of 1 °C per step. Measurements were repeated three times at each temperature.  
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2.2.5  Preparation of samples for fluorescence measurements 
   S-samples were prepared by the heating dissolution method as follows. Tri-PCG-dan (64.2 mg) 
and tri-PCG (1542 mg) were dissolved in acetone (64 mL; the weight ratio of tri-PCG-dan/tri-PCG = 
1/24). The obtained mixture (tri-PCG-dan/tri-PCG) solution was evaporated to remove acetone. Next, a 
predetermined amount of phosphate buffered saline (PBS) (pH = 7.4, 10 mM) was added to the flask 
(total polymer concentration = 0.025 - 15 wt%). After shaking with a vortex mixer for 1 min at r.t., the 
obtained suspension was heated to 65 °C and kept at 65 °C for 1 min, and further stirred by a vortex 
mixer for 1 min at r.t. The flask was immersed in ice-cold water for 2 min and further stirred by a vortex 
mixer for 1 min at r.t. These procedures were repeated until no insoluble particles were observed to give 
tri-PCG-dan/tri-PCG micelle solutions. Tri-PCG-nap/tri-PCG micelle solutions, where the weight ratio 
of tri-PCG-nap/tri-PCG was 0.7/24.3, were also prepared by the same procedure as for 
tri-PCG-dan/tri-PCG. Equal amounts of the obtained tri-PCG-dan/tri-PCG micelle solution and 
tri-PCG-nap/tri-PCG micelle solution were mixed together using a vortex mixer for 10 sec. The resulting 
S-sample solution was transferred to a glass cuvette and incubated in a water bath at a designated 
temperature. After incubation for predetermined periods, fluorescence spectra were recorded at r.t. after 
60 min incubation at r.t. unless otherwise noted.   
   D-samples were prepared by the freeze-dry with PEG/dispersion method as follows. Tri-PCG-dan 
(28.6 mg), tri-PCG (686.4 mg) and PEG2000 (71.5 mg) were mixed (weight ratio = 1/24/2.5) and 
dissolved in acetone (7 mL). The solution was dissolved in pure water (70 mL) with stirring, then 
evaporated to remove acetone. The obtained aqueous solution was freeze-dried to give the mixture 
sample in powder form. A predetermined amount of PBS (pH = 7.4, 10 mM) was added to the powder 
(total polymer concentration = 15 wt%) in a test tube. The test tube was shaken by a vortex mixer for 1 
min to give a macroscopically uniform milky dispersion. A dispersion of the mixture of tri-PCG-nap, 
tri-PCG and PEG2000 (weight ratio = 0.7/24.3/2.5) was prepared by the same procedure. Equal amounts 
of the obtained tri-PCG-dan/tri-PCG/PEG2000 dispersion and tri-PCG-nap/tri-PCG/PEG2000 dispersion 
were mixed with stirring using a vortex mixer for 10 sec to give D-samples. The resulting dispersion was 
transferred to a glass cuvette and incubated in a water bath at a designated temperature. After incubation 
for predetermined periods, fluorescence spectra were recorded at r.t. after 60 min incubation at r.t. unless 
21 
 
otherwise noted. 
 
2.2.6  TEM observation 
   The micelle morphology was observed by transmission electron microscopy (TEM) (JEM-1400, 
JEOL, Tokyo, Japan) with acceleration voltage at 80 kV. The S-sample and D-sample for TEM were 
prepared by the same methods described above using pure water instead of PBS, and diluted with pure 
water to 2 wt%. An aliquot (4 µL) of the sample solution (2 wt%) was put on a STEM 150 Cu grid with 
hydrophilic polyvinylbutyral (PVB-C15) membrane (Okenshoji Co. Ltd., Tokyo, Japan). After 5 min 
incubation at r.t., the sample was dried by N2 gas, and negatively stained with 1 wt% hexaammonium 
heptamolybdate tetrahydrate aqueous solution followed by 1 min incubation and drying with N2 gas 
before observation. 
 
2.3  Results and Discussion 
2.3.1  Synthesis of tri-PCG, tri-PCG-dan and tri-PCG-nap and sol-to-gel transition 
   The synthesis of tri-PCG-dan and tri-PCG-nap were successfully carried out from tri-PCG 
according to Scheme 2. The characterization results of tri-PCG, tri-PCG-dan and tri-PCG-nap are shown 
in Table 1. 1H-NMR spectra, SEC elution profiles and emission/excitation spectra of tri-PCG-dan and 
tri-PCG-nap are shown in Figures 2-5. The purities of tri-PCG-dan and tri-PCG-nap were confirmed by 
SEC analysis (Figure 4): no low-molecular-weight compounds were detected. The Mw of tri-PCG-dan 
was higher than those of the other copolymers, because the low-molecular-weight fraction was removed 
during the reprecipitation process. The degree of substitution of dan and nap groups per terminal OH 
groups was calculated to be 71.6% and 97.0%, respectively, by 1H-NMR integration. The introduction of 
the nap group was quantitative, but the dan group incorporation was not. The tri-PCG-dan sample 
contained about 50% of tri-PCG molecules having only one dan group, but this will not affect the 
investigation of polymer chain transfer by FRET. The mixing ratios of tri-PCG-dan and tri-PCG-nap to 
tri-PCG were 1/24 and 0.7/24.3 to adjust the molar ratio of dan/nap = 1/1. 
   The tri-PCG solution (15 wt%) showed a sol-to-gel transition point at 35 °C (Figure 6), and the 
mixtures of tri-PCG-dan/tri-PCG micelle solution and tri-PCG-nap/tri-PCG micelle solution (S-sample) 
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showed the same (35 °C) sol-to-gel transition point as the tri-PCG solution. D-samples (mixture of 
tri-PCG-dan/tri-PCG micelles and tri-PCG-nap/tri-PCG micelles prepared by freeze-dry with 
PEG/dispersion method) showed sol-to-gel transition points at 36 °C. 
 
 
Scheme 1. Synthesis of PCGA-b-PEG-b-PCGA triblock copolymer (tri-PCG) 
 
O
O
On
O
O
1-xm
x O
H
m1-x x
O
O
O
OH
N
SHN O
O
HO
O
O
H
O
O
O
On
O
O
1-xm
x O
R
m1-x x
O
O
O
OR
N
SN
H
O
OO
O
R =
+ or
or
 
Scheme 2. Synthesis of tri-PCG-dan and tri-PCG-nap. 
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Table 1. Characteristics of tri-PCG, tri-PCG-dan and tri-PCG-nap 
Code 
DP of 
CLa) 
DP of 
GAb) 
CL/GAc) 
Mn 
(Da)d) 
Mw 
(Da)e) 
Mw/Mne) DS (%)f) 
tri-PCG 14.2 4.2 3.4 5,200 6,100 1.44 - 
tri-PCG-dan 19.9 6.3 3.2 7,400 8,000 1.28 71.6 
tri-PCG-nap 13.0 4.0 3.3 5,300 6,300 1.47 97.0 
a) Degree of polymerization of CL unit in a PCGA segment estimated by 1H-NMR. 
b) Degree of polymerization of glycolic acid (GA) unit in a PCGA segment estimated by 1H-NMR. 
c) Molar ratio of CL/GA in a PCGA segment calculated by 1H-NMR. 
d) Number-average molecular weight estimated by 1H-NMR. 
e) Weight-average molecular weight and polydispersity index estimated by SEC. 
f) Degree of substitution of dan or nap group/OH estimated by 1H-NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 1H-NMR spectra of tri-PCG in CDCl3. 
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Figure 3. 1H-NMR spectra of (a) tri-PCG-dan and (b) tri-PCG-nap in CDCl3 
 
(a) 
(b) 
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Figure 4. Elution profiles of size exclusion chromatography for tri-PCG, tri-PCG-dan and tri-PCG-nap. 
 
 
Figure 5. Emission and excitation spectra of the sample solutions. 
Solid line: emission spectrum of tri-PCG-nap/tri-PCG micelle solution (excitation at 290 nm), long dashed 
line: excitation spectrum of tri-PCG-nap/tri-PCG micelle solution (emission at 370 nm), short dashed line: 
emission spectrum of tri-PCG-dan/tri-PCG micelle solution (excitation at 370 nm), dotted line: excitation 
spectrum of tri-PCG-dan/tri-PCG micelle solution (emission at 530 nm). Total polymer concentration = 
0.025 wt%. 
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Figure 6. Phase diagram of tri-PCG in PBS. ○: sol, ■: gel, △: precipitate. Inserts are photographs of the 
polymer solutions (15wt%) at 32°C and 35°C. 
 
2.3.2  Morphology of the micelles 
   To evaluate the morphology of the micelles in S-sample and D-sample, TEM observation of the 
sample solutions (or dispersions) was carried out. The results are shown in Figure 7. In Figure 7a, 
spherical particles with 40-60 nm diameters were observed for S-sample. The diameters were within 
reasonable level for flower-like polymeric micelles of tri-PCG. On the other hand, in Figures 7b and c, 
larger particles were observed for D-sample in addition to the similar size particles showed as seen in 
S-sample (Figure 2a). Some of the larger particles showed somewhat rugged shapes (Figure 2c). These 
results mean that some of D-sample micelles existed as aggregates and the other did not, showing good 
agreement with its turbid appearance. 
 
 
 
 
 
 
15wt%, 35°C 
15wt%, 32°C 
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Figure 7. TEM images for S-sample (a) and D-sample (b, c). 
 
2.3.3  FRET measurements on S-sample 
   The emission spectra of the S-samples (the mixture of tri-PCG-nap/tri-PCG micelle solution and 
tri-PCG-dan/tri-PCG micelle solution) after mixing at r.t. and further incubation at a predetermined 
temperature for 10 min were recorded. Figure 8a shows emission spectra of each sample before mixing, 
and Figure 8b shows typical examples of the emission spectra of diluted S-samples (copolymer 
concentration = 0.025 wt%) with excitation wavelength at 290 nm after incubation at various 
temperatures. As the incubation temperature increased, the emission intensities at 370 nm assigned to the 
nap group gradually decreased, and the emission at 530 nm assigned to the dan group gradually 
increased. These results indicate the occurrence of FRET from the nap group to the dan group. FRET 
occurs when nap and dan groups exist in close proximity (Förster distance). These results suggest that 
the polymer chain (tri-PCG-dan or tri-PCG-nap) transfers between the micelles, and that the rate of 
polymer chain transfer is dependent on temperature. Therefore, the degree of polymer chain transfer in 
the mixed micelle solution can be evaluated by monitoring FRET. 
   To evaluate the degree of polymer chain transfer (exchange) quantitatively, the emission intensity 
ratio for the peaks at 530 nm (dan) and 370 nm (nap) (I530/I370) was calculated as the polymer chain 
exchange index. Plots of I530/I370 as a function of incubation temperature are shown in Figure 9. The data 
for the homogeneous mixtures of tri-PCG-nap, tri-PCG-dan and tri-PCG (weight ratio = 0.7/1.0/48.3) are 
shown to estimate the FRET efficiency at the equilibrium state after complete polymer chain exchange in 
Figure 9. The emission intensity ratio I530/I370 for homogeneous samples was about 0.22 and remained 
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constant with temperature variation, confirming that FRET efficiency was not dependent on temperature. 
We regarded I530/I370 = 0.217 (the average of observed values) as the theoretical maximum emission 
intensity ratio value where the degree of polymer chain exchange (Dex) = 100%, and I530/I370 = 0.102 
(theoretical value calculated from the additive spectra in Figure 8) as Dex = 0%, as shown on the Y-axis 
on the right side in Figure 9. Therefore, Dex can be defined by the following equation: 
Dex (%) = (Rt - Rmin) / (Rmax - Rmin) × 100 
where Rt is the observed I530/I370 value, Rmax is the I530/I370 value for a homogeneous mixture (= 
0.217), and Rmin is the theoretical value of I530/I370 with no polymer exchange (= 0.102). 
   I530/I370 (and Dex) for the mixture of tri-PCG-nap/tri-PCG micelle solution and 
tri-PCG-dan/tri-PCG micelle solution (S-sample) increased with increasing temperature. This means that 
the rate of polymer chain transfer was greater at higher temperature. Over 48 °C, the Dex value reached a 
plateau at about 87%. Furthermore, the graph was a sigmoidal curve with a threshold at 40-45 °C. In a 
diluted condition (0.025 wt%, sufficiently below gelation concentration), the tri-PCG solution showed a 
higher transition point over 40 °C, which was detected by a diameter change in dynamic light scattering 
(DLS) (data not shown). These results suggest that the increase in Dex along with temperature was not 
only due to kinetic acceleration by the temperature increase, and the polymer transfer rate was 
significantly increased around the sol-to-gel transition temperature. 
   We also investigated the effects of polymer concentration on polymer chain transfer. Figure 10 
shows the time course of the degree of polymer chain exchange (Dex) for various polymer 
concentrations after incubation at 35 °C. The emission spectra of the samples were recorded after 
dilution to 0.025 wt%, because the fluorescence intensity was too large when the concentration was high. 
Upon increasing polymer concentration, the Dex value reached a plateau in a shorter period of time. It is 
quite reasonable that the polymer exchange rate is higher at a higher polymer concentration. Mattice et al. 
reported that the polymer chain exchange rate was very slow at low polymer concentration27 and the 
mechanism of polymer chain exchange was suggested to be micellar merger/splitting at higher polymer 
concentration by dynamic Monte Carlo (MC) simulations32. Our results showed good agreement with 
their hypothesis and provided evidence from an actual system that polymer chain exchange was 
promoted by merger and splitting between micelles at high polymer concentration. Therefore, we 
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confirmed that polymer chain transfer behavior can be examined under higher (15 wt%) polymer 
concentration. 
   Figure 11 shows the time course of Dex for the mixture of tri-PCG-nap/tri-PCG micelle solution 
and tri-PCG-dan/tri-PCG micelle solution (S-sample) with 15 wt% polymer concentration at various 
incubation temperatures. The increase in the Dex value was much faster at higher incubation temperature. 
The rate of polymer chain transfer between the micelles strongly depended on temperature. Polymer 
chain transfer was very slow at 25 °C. On the Basis of the results of DLS measurements, the diameter of 
the tri-PCG micelle was constant at 25 °C (Figure 12). These results suggest that the micelles neither 
merged nor aggregated at 25 °C. At a temperature sufficiently lower than the transition point, PEG chains 
existing at the shell layer of the micelles were adequately hydrated and the hydrophobic cores of the 
micelles were not exposed to the aqueous phase by exclusion volume effects of the PEG chains. This is 
the reason why merger/aggregation of micelles hardly occurred at low temperature even at high polymer 
concentration. After 1 min incubation at 35 °C, the micelle solution underwent gelation, but the Dex 
value still increased for an additional 9 min after gelation. These results indicate that polymer chain 
transfer occurred even after gelation, and the polymer chains could move in the hydrogel. On the other 
hand, at 30 °C, below the sol-to-gel transition temperature, the Dex value also increased gradually. These 
results suggest that some polymer chain transfer occurred below the gelation temperature.  
   We found that the rate of polymer chain transfer was significantly accelerated around the gelation 
temperature. In previous reports, the sol-to-gel transition occurred by association of micelles21-24, and 
polymer chain transfer (exchange) occurred by merger between micelles32. However, it was suggested 
that polymer chain transfer began before the gelation temperature was reached and continued after 
gelation. 
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Figure 8. (a) Emission spectra for each samples before mixing. Solid line: tri-PCG-nap/tri-PCG micelle 
(excitation at 290 nm), dotted line: tri-PCG-dan/tri-PCG micelle (excitation at 290 nm), and 
dashed line: tri-PCG-dan/tri-PCG micelle (excitation at 370 nm). (b) Emission spectra for 
mixture of tri-PCG-nap/tri-PCG micelle solution and tri-PCG-dan/tri-PCG micelle solution 
(S-sample) after incubation at various temperature for 10 min, and the additive spectrum of 
tri-PCG-nap/tri-PCG micelle (excitation at 290nm) (solid line in (a)) and tri-PCG-dan/tri-PCG 
micelle (excitation at 290 nm) (dotted line in (a)). 
Total copolymer concentration = 0.025 wt%. 
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Figure 9. Emission intensity ratio (I530/I370) and degree of polymer chain exchange for homogeneous 
mixture of tri-PCG-nap/tri-PCG-dan/tri-PCG micelle (○), and mixture of tri-PCG-nap/tri-PCG 
micelle solution and tri-PCG-dan/tri-PCG micelle solution (S-sample) (●) after incubation at 
various temperature for 10 min. 
Total polymer concentration = 0.025wt%. 
 
 
Figure 10. Degree of polymer chain exchange for S-sample with different polymer concentrations 
incubated at 35°C. ○: 15 wt%, □: 7.5 wt%, ◇: 2.5 wt%, △: 0.25 wt%, × : 0.025 wt%. 
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Figure 11. Time course of the degree of polymer chain exchange for the mixture of tri-PCG-nap/tri-PCG 
micelle solution and tri-PCG-dan/tri-PCG micelle solution (S-sample) incubated at 35°C (●), 
30°C (■), or 25°C (▲). Total polymer concentration = 15 wt%. 
 
 
Figure 12. Time course of particle size change in tri-PCG micelle solution incubated at various 
temperatures. 35°C (●), 30°C (■), 25°C (▲). Polymer concentration = 0.5 wt%. 
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2.3.4  Comparison of D-samples and S-samples 
   As described in the introduction, we previously discovered that the temperature-responsive 
covalent cross-linking IP formulations prepared by the "freeze-dry with PEG/dispersion" method 
(D-samples) retained the sol state longer (more than 24 h) than the formulations prepared by the usual 
heating dissolution method (S-samples), which undergo gelation typically within 3 h after preparation20. 
We hypothesized that differences in stability (no gelation during incubation at r.t.) between D-samples 
and S-samples are due to differences in the rate of polymer chain transfer at r.t. To confirm this 
hypothesis, we investigated polymer chain transfer for both D-samples (15 wt%) and S-samples for an 
extended period of time at 25 °C. In this experiment, the emission intensity for the samples was 
measured immediately after dilution to 0.025 wt%. The results are shown in Figure 13. Clearly, the 
increase in the Dex value for the S-sample at the initial stage was significantly faster than that of the 
D-sample. After the initial (ca. 10 min) fast increase, the Dex value for the S-sample increased more 
gradually. For the D-sample, no rapid increase at the initial stage was observed and the Dex value 
increased gradually. After 180 min, the Dex values were about 45% and 20% for the S-sample and 
D-sample, respectively. Considering our previous results showing that spontaneous covalent gelation 
occurred in 3 h for S-samples20, the critical degree of polymer exchange for gelation should exist 
between 20% and 45%. It was confirmed that the rate of polymer chain transfer in the S-sample was 
much faster than that in the D-sample at r.t especially at the initial stage. We confirmed that the D-sample 
showed an endothermic peak at 30 °C and the micelle core was in a solid-like semi-crystalline state by 
DSC measurements (Figure 14). Therefore, polymer chain transfer was suppressed in the D-sample 
because it was not in the usual equilibrium state between unimers and micelles. The initial stage polymer 
chain transfer was quite low for the D-sample because the amount of unimers in the D-sample micelle 
solution was extremely low. In addition, the unimers, if they existed, were difficult to incorporate into 
other micelles because the micelle cores were in the solid-like semi-crystalline state. 
   The main reason of the difference between S-samples and D-samples is the difference of the core 
states, which must be derived from the preparation process (freeze-dry or heating dissolution) as follows. 
D-sample was prepared by the freeze-dry with PEG/dispersion method. After freeze-dry, the core of the 
sample was partially crystalized. Although certain part of micelle was aggregated, the PEG molecules, as 
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additives, existed between the micelles in the aggregates, which helped rapid dispersion of the 
D-samples. During this dispersion process, the temperature was kept below the melting temperature. So, 
the crystal formed in the core was not melted, and no water molecule could penetrate into the micelle 
core. As results, the cores of D-sample micelles kept their semi-crystalline state. On the other hand, 
during the process for S-sample preparation (heating dissolution), temperature was raised above the 
melting temperature, and the crystal in the core was melted. But, during the cooling process, 
recrystallization in the micelle core was not proceeded in the presence of solvent (water). So, the core of 
the S-sample micelle became amorphous state. 
   To estimate the degree of polymer chain exchange in S-samples and D-samples during the 
sol-to-gel transition process, the Dex value under continuous temperature increase (from 25 °C to 42 °C, 
1 °C min-1) was monitored (Figure 15). The S-sample showed gelation at 35 °C, and its Dex value 
increased rapidly in the range of 30-37 °C. Thus, polymer chain transfer occurred in advance of gelation, 
and this result shows good agreement with the results shown in Figure 11. The percolation transition of 
associated micelles is considered to be the prevailing mechanism for the sol-to-gel transition. However, 
the association of micelles and polymer chain transfer began before reaching the transition temperature 
of percolation. In contrast, the Dex value of the D-sample gradually increased from 25 °C to 42 °C: no 
rapid increase at a certain temperature was observed. The D-sample showed gelation at 36 °C, where the 
Dex value was about 50%, which was significantly lower than that of the S-sample at the gelation 
temperature (78% at 35 °C). This result indicated that exchange of polymer chains between micelles is 
suppressed in D-samples compared to S-samples. 
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Figure 13. Time course of the degree of polymer chain exchange for S-sample (■) and D-sample (□) 
incubated at 25°C. Total polymer concentration = 15 wt%. 
 
 
 
 
 
 
 
 
 
 
Figure 14. DSC curve for S-sample (mixture of tri-PCG-nap/tri-PCG and tri-PCG-dan/tri-PCG micelle 
solution) and D-sample (mixture of tri-PCG-nap/tri-PCG and tri-PCG-dan/tri-PCG micelle 
dispersion). Total polymer concentration = 15 wt%. 
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Figure 15. Degree of polymer chain exchange in S-sample (■)and D-sample (□) under continuous 
temperature increase (1 °C min-1). The polymer concentration is 15 wt%. 
 
2.4  Conclusion 
   We successfully synthesized PCGA-b-PEG-b-PCGA with naphthalene or dansyl groups covalently 
attached at both termini, tri-PCG-nap and tri-PCG-dan, as FRET donors and acceptors, respectively. The 
FRET observations provided an estimation of polymer chain transfer between the micelles in the mixture 
of tri-PCG-nap/tri-PCG micelles and tri-PCG-dan/tri-PCG micelles (S-sample or D-sample). Polymer 
chain transfer between micelles for the S-sample was strongly dependent on the polymer concentration 
and temperature, and was accelerated at the gelation temperature. It was revealed that polymer chain 
transfer began in advance of gelation, and continued even after gelation. We previously reported that 
covalent cross-linking IP formulations prepared by the "freeze-dry with PEG/dispersion" method 
(D-samples) retained the sol state at r.t. longer compared to S-samples prepared by the heating 
dissolution method20, and hypothesized that polymer chain transfer between micelles was suppressed in 
D-samples, because the micelle cores were in a solid-like semi-crystalline state. In this study, we 
confirmed that polymer chain transfer in D-samples was in fact suppressed compared with S-samples. 
Therefore, the results obtained in this study strongly support our hypothesis. 
 
37 
 
2.5  References 
(1)  Choi, S., Baudys, M. & Kim, S. W. Control of blood glucose by novel GLP-1 delivery using 
biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats. Pharm. Res. 21, 
827-831 (2004) 
(2)  Li, K., Yu, L., Liu, X., Chen, C., Chen, Q. & Ding, J. A long-acting formulation of a polypeptide 
drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel. Biomaterials 
13, 1195-1203 (2013) 
(3)  Yeon, B., Park, M. H., Moon, H. J., Kim, S., Cheon, Y. W. & Jeong, B. 3D culture of 
adipose-tissue-derived stem cells mainly leads to chondrogenesis in poly(ethylene 
glycol)-poly(L-alanine) diblock copolymer thermogel. Biomacromolecules 14, 3256-3266 (2013) 
(4)  Nagahama, K., Ouchi, T. & Ohya, Y. Temperature-induced hydrogels through self-assembly of 
cholesterol-substituted star PEG-b-PLLA copolymers: an injectable scaffold for tissue engineering. 
Adv. Funct. Mater. 18, 1220-1231 (2008) 
(5)  Zhang, Z., Ni, J., Chen, L., Yu, L., Xu, J. & Ding, J. Biodegradable and thermoreversible PCLA–
PEG–PCLA hydrogel as a barrier for prevention of post-operative adhesion. Biomaterials 32, 
4725-4736 (2011) 
(6)  Hong, J. H., Choe, J. W., Kwon, G. Y., Cho, D. Y., Sohn, D. S., Kim, S. W., Woo, Y. C., Lee, C. J. & 
Kang, H. The effects of barrier materials on reduction of pericardial adhesion formation in Rabbits: a 
temperature sensitive poloxamer solution/gel material. J. Surg. Res. 166, 206-213 (2011) 
(7)  Weng, L., Rostambeigi, N., Zantek, N. D., Rostamzadeh, P., Bravo, M., Carey, J. & Golzarian, J. An 
in situ forming biodegradable hydrogel-based embolic agent for interventional therapies. Acta 
Biomater. 9, 8182-8192 (2013) 
(8)  Yu, L., Xu, Wei., Shen, W., Cao, L., Liu, Y., Li, Z. & Ding, J. Poly(lactic acid-co-glycolic 
acid)-poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) thermogel as a novel submucosal 
cushion for endoscopic submucosal dissection. Acta Biomater. 10, 1251-1258 (2014) 
(9)  Fujiwara, T., Mukose, T., Yamaoka, T., Yamane, H., Sakurai, S. & Kimura, Y. Novel 
thermo-responsive formation of a hydrogel by stereo-complexation between PLLA-PEG-PLLA and 
PDLA-PEG-PDLA. Macromol. Biosci. 1, 204-208 (2001) 
38 
 
(10) Jeong, B., Bae, Y. H. & Kim, S. W. Thermoreversible gelation of PEG−PLGA−PEG triblock 
copolymer aqueous solutions. Macromolecules 32, 7064-7069 (1999) 
(11) Chen, C., Chen, L., Cao, L., Shen, W., Yu, L. & Ding, J. Effects of L-lactide and D,L-lactide in 
poly(lactide-co-glycolide)-poly(ethylene glycol)-poly(lactide-co-glycolide) on the bulk states of 
triblock copolymers, and their thermogellation and biodegradation in water. RSC Adv. 4, 8789-8798 
(2014) 
(12) Bae, S. J., Suh, J. M., Sohn, Y. S., Bae, Y. H., Kim, S. W. & Jeong, B. Thermogelling 
poly(caprolactone-b-ethylene glycol-b-caprolactone) aqueous solutions. Macromolecules 38, 
5260-5265 (2005) 
(13) Liu, C. B., Gong, C. Y., Huang, M. J., Wang, J. W., Pan, Y. F., Zhang, Y. D., Li, G. Z., Gou, M. L., 
Wang, K., Tu, M. J., Wei, Y. Q. & Qian, Z. Y. Thermoreversible gel–sol behavior of biodegradable 
PCL-PEG-PCL triblock copolymer in aqueous solutions. J. Biomed. Mater. Res. Part B 84, 165-175 
(2008) 
(14) Jiang, Z., You, Y., Deng, X. & Hao, J. Injectable hydrogels of 
poly(ε-caprolactone-co-glycolide)-poly(ethylene glycol)-poly(ε-caprolactone-co-glycolide) triblock 
copolymer aqueous solutions. Polymer 48, 4786-4792 (2007) 
(15) Jiang, Z., You, Y., Gu, Q., Hao, J. & Deng, X. Effect of microstructures on the phase transition 
behavior of P(CL-GL)-PEG-P(CL-GL) triblock copolymer aqueous solutions. Macromol. Rapid 
Commun. 2008, 29, 1264-1268 
(16) Yu, L., Sheng, W., Yang, D. & Ding, J. Design of molecular parameters to achieve block copolymers 
with a powder form at dry state and a temperature-induced sol-gel transition in water without 
unexpected gelling prior to heating. Macromol. Res. 21, 207-215 (2013) 
(17) Yoshida, Y., Kawahara, K., Inamoto, K., Mitsumune, S., Ichikawa, S., Kuzuya, A. & Ohya, Y. 
Biodegradable injectable polymer systems exhibiting temperature-responsive irreversible sol-to-gel 
transition by covalent bond formation. ACS Biomater. Sci. Eng. 3, 56-67 (2017) 
(18) Yoshida, Y., Takai, H., Kawahara, K., Mitsumune, S., Takata, K., Kuzuya, A., & Ohya, Y.  
Biodegradable injectable polymer systems exhibiting longer and controllable duration time of the gel 
state. Biomater. Sci. 5, 1304-1314 (2017) 
39 
 
(19) Yoshida, Y., Takahashi, A., Kuzuya, A., & Ohya, Y. Instant preparation of a biodegradable injectable 
polymer formulation exhibiting a temperature-responsive sol-gel transition. Polym. J. 46, 632-635 
(2014) 
(20) Yoshida, Y., Takata, K., Takai, H., Kawahara. K., Kuzuya, A., & Ohya, Y. Extemporaneously 
preparative biodegradable injectable polymer systems exhibiting temperature-responsive irreversible 
gelation. J. Biomat. Sci. Polym. E. 28, 1427-1443 (2017) 
(21) Yu, L., Chang, G., Zhang, H. & Ding, J. Temperature-induced spontaneous sol–gel transitions of 
poly(D,L-lactic acid-co-glycolic acid)-b-Poly(ethylene glycol)-b-poly(D,L-lactic acid-co-glycolic 
acid) triblock copolymers and their end-capped derivatives in water. J. Polym. Sci., Polym. Chem. 45, 
1122-1133 (2007) 
(22) Zhang, H., Yu, L. & Ding, J. Roles of hydrophilic homopolymers on the 
hydrophobic-association-induced physical gelling of amphiphilic block copolymers in water. 
Macromolecules 41, 6493-6499 (2008) 
(23) Yang, Z. & Ding, J. A thermosensitive and biodegradable physical gel with chemically crosslinked 
nanogels as the building block. Macromol. Rapid Commun. 29, 751-756 (2008) 
(24) Yu, L., Zhang, Z., Zhang, H. & Ding, J. Mixing a sol and a precipitate of block copolymers with 
different block ratios leads to an injectable hydrogel. Biomacromolecules 10, 1547-1553 (2009) 
(25) Yamamoto, Y., Yasugi, K., Harada, A., Nagasaki, Y. & Kataoka, K. Temperature-related change in the 
properties relevant to drug delivery of poly(ethylene glycol)-poly(D,L-lactide) block copolymer 
micelles in aqueous milieu. J. Controlled Release 82, 359-371 (2002) 
(26) Jule, E., Yamamoto, Y., Thouvenin, M., Nagasaki, Y. & Kataoka, K. Thermal characterization of 
poly(ethylene glycol)-poly(D,L-lactide) block copolymer micells based on pyrene excimer formation. 
J. Controlled Release 97, 407-419 (2004) 
(27) Wang, Y., Balaji, R., Quirk, R. P. & Mattice, W. L. Detection of the rate of exchange of chains 
between micelles formed by diblock copolymers in aqueous solution. Polym. Bull. 28, 333-338 
(1992) 
(28) Wang, Y., Kausch, C. M., Chun, M., Quirk, R. P. & Mattice, W. L. Exchange of chains between 
micelles of labeled polystyrene-block-poly(oxyethylene) as monitored by nonradiative singlet 
40 
 
energy transfer. Macromolecules 28, 904-911 (1995) 
(29) Tian, M., Qin, A., Ramireddy, C., Webber, S. E. & Munk, P. Hybridization of block copolymer 
micelles. Langmuir 9, 1741-1748 (1993) 
(30) Lu, J., Bates, F. S. & Lodge, T. P. Remarkable effect of molecular architecture on chain exchange in 
triblock copolymer micelles. Macromolecules 48, 2667-2676 (2015) 
(31) Wu, P. & Brand, L. Resonance energy transfer: methods and applications. Analytical Biochemistry 
218, 1-13 (1994) 
(32) Haliloglu, T., Bahar, I., Erman, B. & Mattice, W. L. Mechanisms of the exchange of diblock 
copolymers between micelles at dynamic equilibrium. Macromolecules 29, 4764-4771 (1996) 
 41 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
Peptide drug release behavior from the 
biodegradable temperature-responsive 
injectable hydrogels exhibiting irreversible 
gelation
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3.1  Introduction 
   Various temperature-responsive water-soluble polymers have been investigated for application in 
drug delivery systems (DDSs)1-9. Of these, several polymers in aqueous solution exhibit a 
temperature-responsive sol-to-gel transition between room temperature (r.t.) and body temperature and 
can thus be used as injectable polymer (IP) systems. Such polymer solutions can be mixed with 
water-soluble bioactive reagents such as proteins, peptides, or living cells before injection, and form a 
hydrogel entrapping these reagents at the injection site in the body. If the polymer can be hydrolyzed to 
low-molecular-weight compounds that can be metabolized or excreted from the body, such 
biodegradable IP systems could potentially act as implantable minimally invasive sustained drug release 
systems10-12. 
   There have been many reports on drug release from hydrogels. The release rates of drugs from 
hydrogels are influenced by several factors, such as the hydrophilicity/hydrophobicity (solubility) and 
molecular weight of the drug, the degradation rates of the hydrogel, the mesh size of the network, and the 
diffusion constant of the drug in the hydrogel13. In general, temperature-responsive biodegradable IP 
hydrogels, once formed in the body, are likely to quickly revert to the sol state (typically in less than 24 
h) at the injection site, where there is a large amount of body fluid14. This is because the gelation of such 
an IP system is caused by non-covalent (hydrophobic) interactions, and gel formation is an equilibrium 
process affected by local conditions such as concentration, pH, and temperature. This phenomenon may 
cause rapid disappearance of the hydrogel and more rapid release of bioactive agents than intended. 
   To address this problem, we recently reported the generation of biodegradable 
temperature-triggered covalent gelation systems exhibiting longer and controllable durations of the gel 
state by using a "mixing strategy"14-16. We synthesized a tri-block copolymer of 
poly(ε-caprolactone-co-glycolic acid) (PCGA), poly(ethylene glycol) (PEG), PCGA-b-PEG-b-PCGA 
(tri-PCG), and tri-PCG with acryloyl groups attached at both termini (tri-PCG-Acryl) (Figure 1). A 
mixture of tri-PCG-Acryl micelle solution and tri-PCG micelle solution containing 
dipentaerythritolhexakis(3-mercaptopropionate) (DPMP) (Figure 1) as a hydrophobic hexa-functonal 
polythiol exhibited an irreversible sol-to-gel transition by covalent cross-linking using a bio-orthogonal 
Michael-addition-type thiol-ene reaction in response to a temperature increase15,16. The mixed micelle 
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solution remained in the sol state just after mixing at r.t., but underwent gelation in response to a 
temperature increase. Once formed, the hydrogel stayed in the gel state even after cooling. In this system, 
the acryloyl groups at the copolymer termini and the thiol groups of DPMP existed separately in different 
micelles just after mxing. Covalent bond formation between the acryloyl and thiol groups occurred only 
upon sol-to-gel transition induced by a temperature increase, since this temperature rise induced 
inter-micellar aggregation due to hydrophobic interactions, resulting in a physically cross-linked 
hydrogel. During aggregation process, the micelle cores fused and subsequently the thiol groups of 
DPMP in the tri-PCG micelle core covalently cross-linked with the acryloyl groups via the 
Michael-addition-type thiol-ene reaction. This system existed for a longer and controllable duration time 
in the gel state. The duration time of the gel state after subcutaneous injection in vivo could be altered 
easily from 1 day to more than 60 days simply by changing the mixing ratio of DPMP/tri-PCG and 
tri-PCG-Acryl15. 
   Peptides are becoming increasingly important as drugs due to their activity, target specificity, 
tolerability, and availability. However, peptides must be administered via the parenteral route because 
their half-life in the body is extremely short and their oral absorption is poor. Consequently, when 
continuous exposure to the peptide drug is needed, continuous infusion or multiple injections are 
required to achieve therapeutic efficacy, which is inconvenient and distressing for patients. Thus, there is 
a need to develop sustained release parenteral formulations, where a single injection allows the drug to 
be released over a period of weeks, months, or even years17,18. 
   As described above, we previously developed a biodegradable temperature-triggered IP system 
exhibiting covalent gelation using a bio-orthogonal reaction and controllable duration times of the gel 
state. This system should have potential utility as a drug deposition method allowing the sustained 
release of peptide drugs. As far as we were aware, there has been no report on the drug release behavior 
using temperature-triggered covalent gelation system. In this study, we evaluated this IP system as a 
sustained peptide drug release device by studying the release behavior of a peptide from hydrogels 
prepared using our IP system. We chose glucagon-like peptide-1 (7-36 amide) (GLP-1) as the peptide 
model drug. GLP-1 holds promise for the treatment of type 2 diabetes but must be continuously infused 
or administered by multiple injections because of its extremely short half-life19-21. This is the first report 
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on the drug release behavior using biodegradable temperature-responsive covalent gelation system 
exhibiting long-term release of peptide drugs. 
 
 
Figure 1. Structures of the polymers and polythiol used in this study. 
 
3.2  Experimental procedure 
3.2.1  Materials 
   Tri-PCG-1 and tri-PCG-2 were synthesized by the ring-opening polymerization of ε-caprolactone 
(CL) glycolide (GL) in the presence of PEG (molecular weight (Mw) = 1500 Da) according to the 
methods reported previously14. The Mn of PCGA segments, the total Mn, and the molar ratio of glycolic 
acid (GA) units to CL units in the tri-PCG-1 copolymer (CL/GA) were 1950, 5400 Da, and 3.4, 
respectively, and for tri-PCG-2 the values were 1250, 4000 Da, and 3.9, respectively (Table 1). 
Tri-PCG-Acryl was synthesized from tri-PCG-2 by the method described previously15. The total Mn and 
the degree of substitution by acryloyl groups were 4200 Da, and 91%, respectively (Table 2). GLP-1 
(7-36 amide) was purchased from Aviva Systems Biology, Corp. (San Diego, CA, USA). DPMP was a 
gift from SC Organic Chemical Co., Ltd. (Osaka, Japan). Fetal calf serum (FCS) was obtained from 
Thermo Fisher Scientific (Waltham, MA, USA). Eagle's minimum essential medium (E-MEM) was 
purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Mouse fibroblast NCTC clone 929 (L929) 
cells were obtained from the Health Science Research Resources Bank (HSRRB, Osaka, Japan). 
Spague-Dawley (SD) rats (7 weeks old, female, 180 g average body weight) were purchased from Japan 
SLC, Inc. (Hamamatsu, Japan). Water was purified by a Milli-Q (Merck Millipore, Billerica, MA, USA) 
system. All other reagents and organic solvents were of commercial grade and were used without further 
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purification. 
 
Table 1. Characterization of PCGA-b-PEG-b-PCGA triblock copolymers (tri-PCGs). 
Code DP of CLa) DP of GAb) CL/GAc) Mn (Da)d) Mw (Da)e) Mw/Mne) 
tri-PCG-1 14.6 4.3 3.4 5,400 6,900 1.38 
tri-PCG-2 9.9 2.6 3.9 4,000 4,800 1.38 
a) The degree of polymerization of ε-caprolactone unit in a PCGA segment was calculated using 1H-NMR. 
b) The degree of polymerization of glycolic acid unit in a PCGA segment was calculated using 1H-NMR. 
c) Molar ratio of CL/GA in a PCGA segment estimated using 1H-NMR. 
d) Number-average of the molecular weight estimated using 1H-NMR. 
e) Weight-average of the molecular weight and the polydispersity index estimated using SEC. 
 
Table 2. Charcterization of tri-PCG-Acryl 
Code Mn (Da)a) Mw (Da)b) Mw/Mnb) DS (%)c) 
tri-PCG-Acryl 4,200 5,100 1.40 91 
a) Number-average of the molecular weight estimated using 1H-NMR. 
b) Weight-average of the molecular weight and the polydispersity index estimated using SEC. 
c) Degree of substitution of the acryloyl group calculated using 1H-NMR. 
 
3.2.2  Preparation of the IP Formulations 
   The IP formulations were prepared as reported previously15. DPMP-loaded tri-PCG micelle 
solution (Solution A) was prepared as follows. Tri-PCG and DPMP were placed in a glass vial and 
dissolved with a small amount of acetone at r.t. The solution was dropped into pure water in a flask 
stirred at r.t. for 10 min, and then evaporated to remove the acetone. The aqueous solution was 
lyophilized to obtain powdery DPMP-loaded tri-PCG micelles. The powder was placed in a glass vial 
and a predetermined amount of PBS was added. After mixing with a vortex mixer for 1 min at r.t., the 
obtained suspension was heated to 65 °C and kept at 65 °C for 1 min, then mixed using a vortex mixer 
for 1 min at r.t. The glass vial was immersed in iced-cold water for 2 min and mixed with a vortex mixer 
for 1 min at r.t. These procedures were repeated until no insoluble particles were observed to give 
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DPMP-loaded tri-PCG micelle solution (Solution A). 
   Tri-PCG-Acryl micelle solution (Solution B) was prepared as follows. Tri-PCG-Acryl was placed 
in a glass vial and PBS was added. After mixing with a vortex mixer for 1 min at r.t., the obtained 
suspension was heated to 65 °C and kept at 65 °C for 10 s, then further mixed using a vortex mixer for 1 
min at r.t. These procedures were repeated until no insoluble particles were observed to give 
tri-PCG-Acryl micelle solution (Solution B). 
   Finally, Solution A and Solution B were mixed at desired ratios to give IP formulations. The IP 
formulations are expressed as F(P1/D+PAx), where P1, /D, and +PAx denote the presence of tri-PCG-1 
added, the presence of DPMP added, and the amount of tri-PCG-Acryl added was x wt% in total 
polymers. 
 
3.2.3  In vitro Release Test of GLP-1 
   IP formulations F(P1/D+PA40) containing GLP-1 were prepared as follows. A predetermined 
amount of GLP-1 was dissolved in Solution A (total polymer concentration = 26 wt%) by mixing and 
sonication, and the solution was then mixed with Solution B (total polymer concentration = 26 wt%). 
The pH was adjusted to 7.4 with 1N NaOH aqueous solution or 1N HCl aqueous solution, and the total 
polymer concentration was adjusted to 25 wt% by the addition of PBS. The mixing ratio of solution 
A/solution B was 3/2, with the content of tri-PCG-Acryl in the total polymer being 40 wt%, 
F(P1/D+PA40). As a control, IP formulation containing only tri-PCG-1 (without DPMP or 
tri-PCG-Acryl) and GLP-1 F(P1) was prepared by a similar method using only Solution A. The GLP-1 
concentration in each IP formulation was 7.5 mg/mL. 
   Each formulation (200 µL) was placed in a glass vial and incubated at 37 °C for 30 min to obtain a 
hydrogel, then 1 mL of PBS as a release medium was gently added. At each sampling time, 0.6 mL of 
supernatant was removed and measured, and 0.6 mL fresh PBS was added to the vial, and the sample 
was then further incubated at 37 °C. The amount of GLP-1 in the sample solution was determined using 
a reversed-phase high-performance liquid chromatography (RP-HPLC) system (Waters, Milford, MA, 
USA) (column: Vydac 218TP54 (4.6 mm × 250 mm), eluent: acetonitrile containing 0.1% trifluoroacetic 
acid (TFA)/water containing 0.1% TFA, 1/4 to 4/1 linear gradient for 25 min, flow rate: 0.8 mL/min, 
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detector: UV at 210 nm). 
 
3.2.4  Cytotoxicity 
   The viability of L929 mouse fibroblast cells after incubation with each sample for 24 h was 
investigated using a WST-8 assay (Dojindo, Tokyo, Japan). L929 mouse fibroblast cells (100 µL, 2.5 × 
103 cells/well) in E-MEM containing 10% fetal bovine serum (FBS) were seeded in a 96-well microplate 
and cultured in a humidified atmosphere containing 5% CO2 at 37 °C. After preincubation for 24 h, all 
the medium supernatant was removed and added to 90 µL of fresh medium. Then, 10 µL of medium 
containing an IP formulation was added to each well and further incubated for 21 h. The medium 
supernatant was removed again from the wells, and the cells in the wells were washed with PBS twice. 
Thereafter, 90 µL of fresh medium and WST-8 reagent (10 µL) were added to the wells, and incubation 
was continued for a further 3 h. The microplates were read at 450 nm using a microplate reader. The 
average background absorbance from the control wells was subtracted from the sample data. The values 
for each sample were in the linear region of the standard curve for the WST-8 assay. Data are expressed 
as the means and SD (n = 6). Cell viability was calculated using the following equation: Cell viability (%)  = 𝑁𝑁 𝑁𝑁⁄  × 100 
where Nt and Nc are the number of cells with or without IP formulation after 21 h of incubation, 
respectively. 
 
3.2.5  In vivo Experiments 
   The F(P1/D+PA40) formulation (500 µL) containing GLP-1 was administrated by syringe with a 
25 G needle subcutaneously in the back neck of a rat after anesthetizing with isoflurane. F(P1) 
containing GLP-1, F(P1/D+PA40) without GLP-1, and GLP-1 in PBS (pH 7.4) were used as controls. 
The volume of all samples was 500 µL, and the concentration of GLP-1 was 7.5 mg/mL. 
   At each sampling time (2 h-25 days), 250 µL blood samples were obtained from the tail vein using 
a blood collection tube (BD Microtainer with K2EDTA, Becton, Dickinson and Company, Franklin 
Lakes, NJ, USA). The blood samples were treated with 5 µL of dipeptidyl peptidase IV inhibitor (Merck 
Millipore, Billerica, MA, USA) and centrifuged (9100 g, 10 min, 4 °C) to obtain the plasma. The amount 
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of active GLP-1 in the plasma was determined using an ELISA kit (GLP-1 active form assay kit, 
Immuno-Biological Laboratories Co., Ltd., Shizuoka, Japan). The results were expressed as mean ±SE (n 
= 4-6). Statistical comparisons were made using a Student's t-test. A value of p < 0.05 was considered 
significant. These experiments followed the guidelines for animal experiments at Kansai University. The 
experiment was approved by the Ethical Committee for Animal Experiments of Faculty of Chemistry, 
Materials and Bioengineering, Kansai University (17 April, 2017, Identification number 1709). 
 
3.2.6  Rheological Measurements 
   The physical properties of the formulations after soaking in PBS (release test) or after 
subcutaneous injection into rats were investigated at 37 °C by rheological measurements using a 
dynamic rheometer (Thermo HAAKE RS600, Thermo Fisher Scientific, Waltham, MA, USA). A solvent 
trap was used to prevent solvent vaporization. The diameter of the parallel plate was 35 mm, and the gap 
was 0.2 mm. The controlled stress and frequency were 0.4 Pa and 1.0 rad/s, respectively. 
 
3.3  Results and Discussion 
3.3.1  Synthesis of tri-PCGs and tri-PCG-Acryl and sol-to-gel transition containing GLP-1 
   Tri-PCGs (tri-PCG-1 and tri-PCG-2) and tri-PCG-Acryl were successfully synthesized according 
to the methods reported previouly15 (Schemes 1 and 2). Several characteristics of the polymers are 
shown in Table 1 and 2. The IP formulations were typically prepared by mixing DPMP-loaded tri-PCG 
micelles in Phosphate buffered saline (PBS) (Solution A) and tri-PCG-Acryl micelles in PBS (Solution 
B) at a mixing ratio A/B = 3/2, with the weight content of tri-PCG-Acryl in the total polymer being 40%. 
This IP formulation is denoted as F(P1/D+PA40), where P1, /D, and +PA40 denote the presence of 
tri-PCG-1 added, the presence of DPMP added, and the amount tri-PCG-Acryl added was 40 wt% in 
total polymers, respectively. The control formation, prepared using only tri-PCG-1 or tri-PCG-Acryl, is 
denoted as F(P1) or F(PA). The phase diagrams for tri-PCG-1 and tri-PCG-Acryl are shown in Figure 2. 
Both these polymer solutions (25 wt%) adopted a gel state at 37 °C. 
   The sol-to-gel transition behavior of the F(P1/D+PA40) and F(P1) formulations containing GLP-1 
are shown in Figure 3. Both formulations showed a sol-to-gel transition in response to a temperature 
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increase from 25 to 37 °C. The presence of GLP-1 had almost no effects on the sol-to-gel transitions of 
these formulations (Figure 4), and the transition temperatures were between 25 and 37 °C. After cooling 
to 4 °C, F(P1) containing GLP-1 adopted the sol state, showing that the sol-to-gel transition was 
reversible. In contrast, F(P1/D+PA40) containing GLP-1 remained in the gel state after cooling, showing 
that the sol-to-gel transition was irreversible. These behaviors are in accordance with our earlier 
observations in the absence of GLP-115. Consequently, the presence of GLP-1 had no effect on the phase 
transition irreversibility of the formulation. 
 
 
Scheme 1. Synthesis of PCGA-b-PEG-b-PCGA triblock copolymer (tri-PCG). 
 
 
 
Scheme 2. Synthesis of tri-PCG-Acryl 
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Figure 2. Phase diagram of (a) tri-PCG and (b) tri-PCG-Acryl. ●: sol, ●: gel, ●: sol (syneresis). 
Gelation temperature (Tgel) of each concentration was indicated. 
 
 
 
Figure 3. Photographs of (a) F(P1) hydrogel containing GLP-1 and (b) F(P1/D+PA40) hydrogel 
containing GLP-1 after heating at 37°C for 1 min and subsequent cooling at 4°C for 1 min. 
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Figure 4. Comparison of gelation temperature in the presence or absence of GLP-1 for (a) tri-PCG and 
(b) tri-PCG-Acryl. ●: sol, ●: gel, ●: sol (syneresis). The polymer concentration = 25 wt%. 
Gelation temperature (Tgel) of each sample was indicated. 
 
3.3.2  In vitro release test of GLP-1 from hydrogels 
   We next investigated the in vitro release behavior of GLP-1 from the formulations. Figure 5 shows 
the cumulative amount of GLP-1 released from F(P1/D+PA40) and F(P1) hydrogels at 37 °C in vitro. 
Both hydrogels showed rapid release of GLP-1 during the first two days, and the release rate from F(P1) 
was higher than that from F(P1/D+PA40). On Day 2, the cumulative amount of GLP-1 released from 
F(P1) and F(P1/D+PA40) was about 59% and 38%, respectively. We previously reported that irreversible 
F(P1/D+PAx) IP hydrogels with higher DPMP and tri-PCG-Acryl content showed a longer swelling 
ratio compared with hydrogel without cross-linking (F(P1)) and compared with hydrogels with lower 
DPMP and tri-PCG-Acryl content. This lower swelling was due to the higher cross-linking densities of 
these gels15. The mesh size of a hydrogel increases due to swelling and cross-linking density correlates 
with the swelling ratio22. The main reason for the more rapid release of GLP-1 from F(P1) compared to 
F(P1/D+PA40) hydrogel is likely due to differences in the swelling ratios and diffusion coefficients of the 
two gels. Figure 6 shows photographs of the hydrogels taken during the release tests. The F(P1) 
hydrogel adopts a highly swollen state within 2 h and the formulation is essentially a sol after Day 1. By 
Day 2, the release of GLP-1 from F(P1) becomes gradual. As shown in Figure 6, although F(P1) reverts 
to the sol state completely by Day 30, 100% cumulative release is not attained. The GLP-1 molecule can 
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adsorb onto the polymer chains by hydrophobic interactions23, and GLP-1 may be unstable due to 
spontaneous hydrolysis; consequently, 100% of the GLP-1 molecules could not be detected by 
reversed-phase high-performance liquid chromatography (RP-HPLC) analysis. On the other hand, the 
release of GLP-1 from the F(P1/D+PA40) hydrogel became very slow after Day 2. As shown in Figure 6, 
F(P1/D+PA40) remained in the gel state even after 30 days. The storage modulus (G') (4202 Pa) of 
F(P1/D+PA40) was larger than the loss modulus (G") (326 Pa) and was similar to that of the sample on 
Day 0 (4696 Pa) (Table 3). As described above for F(P1), not all the GLP-1 molecules could be detected 
by RP-HPLC analysis. Regardless, some GLP-1 remained inside the hydrogel and was released very 
slowly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Cumulative release of GLP-1 (%) in vitro from F(P1) hydrogel containing GLP-1 (〇) and 
F(P1/D+PA40) hydrogel containing GLP-1 (□). The data are shown as the mean ±SD (n = 
3). 
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Figure 6. Photographs of (a) F(P1) hydrogel containing GLP-1 and (b) F(P1/D+PA40) hydrogel 
containing GLP-1 during the in vitro release test. 
 
Table 3. Physical properties of the hydrogels during release tests and in vivo experiments. 
Formulation In vitro or vivo Day G' (Pa) G" (Pa) 
 
in vitro 
0 353 99 
F(P1) 30 N.D. 1 N.D. 1 
 in vivo 25 N.D. 2 N.D. 2 
 
in vitro 
0 4694 569 
F(P1/D+PA40) 30 4202 326 
 in vivo 25 1147 364 
1 Not detected because of being dissolved, 2 not detected because of disappearance. 
 
3.3.3  Cytotoxicity 
   To evaluate the cytocompatibilities of the IP formulations, we investigated the cytotoxicity of each 
formulation and their components towards L929 mouse fibroblast cells. The experiments were under 
dilute conditions (< 1 wt%), below the critical gelation concentration of each polymer. The results are 
shown in Figure 7. F(P1) (tri-PCG solution) exhibited no cytotoxicity over the concentration range tested. 
In contrast, F(P1/D) (tri-PCG micelle entrapping DPMP solution: (Solution A)) and F(PA) 
(tri-PCG-Acryl micelle solution: (Solution B)) showed weak cytotoxicity at concentrations above 0.01 
wt% and 0.1 wt%, respectively. Liu et al. reported that oligo-thiols such as dithiothreitol (DTT) are 
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cytotoxic towards NIH/3T3 fibroblasts and rat bone marrow mesenchymal stem cells (BMSCs)24. 
Klouda et al. reported that polymers with multivalent acryloyl groups showed cytotoxicity25. Our results 
are therefore in agreement with these earlier reports. The thiol groups of DPMP in F(P1/D) and the 
acryloyl groups in F(PA) exhibited cytotoxicity, probably because of their interaction with the cell 
membrane. In contrast, the cytotoxicity of F(P1/D+PA50) was negligible, similar to that of F(P1). These 
results suggest that the thiol groups of DPMP and the acryloyl groups of tri-PCG-Acryl reacted with each 
other, decreasing the number of both functional groups, and that the reaction products exhibited no 
cytotoxicity. Consequently, F(P1/D+PA50) showed no significant cytotoxicity. 
 
 
Figure 7. Cell viability of L929 fibroblast cells incubated in the presence of F(P1) (●), F(P1/D) 
(◆), F(PA) (▲) and F(P1/D+PA50) (■) in E-MEM containing 10% Fetal calf serum 
(FCS) at 37 °C for 21 h. 
 
3.3.4  Plasma GLP-1 concentration in SD rats 
   We investigated the in vivo plasma concentration of GLP-1 after subcutaneous injection of the 
formulations into rats (Figure 8). We used an ELISA system to detect only active GLP-1; inactivated 
GLP-1 is not detectable by this system. GLP-1 disappeared from the plasma very quickly following the 
 55 
 
injection of the GLP-1 solution: some GLP-1 was detected in the plasma after 2 h, but essentially none 
was detected after 1 day. This is as expected because the half-life of GLP-1 after subcutaneous injection 
is very short (t1/2 = 9 min)21. The injection of F(P1) formulations resulted in much higher plasma GLP-1 
levels compared to the GLP-1 solution at 2 h, suggesting that the F(P1) hydrogel provided a delayed 
effect compared to the solution, allowing GLP-1 to be absorbed from the injection site and transferred to 
the blood circulation. The plasma GLP-1 level subsequently decreased rapidly to 100 ng/L after 19 days, 
which is slightly higher than the level found in the control rats. The plasma GLP-1 level decreased to the 
control level 25 days after the injection of F(P1) hydrogel. These results are in relatively good agreement 
with the in vitro release tests (Figure 5): rapid, early release of GLP-1 from F(P1) hydrogel, then 
continuous sustained release from the sol state polymer chains acting as adsorbents in the subcutaneous 
space. F(P1/D+PA40) hydrogel also provided a relatively high plasma GLP-1 level 2 h after injection, 
similar to that of the GLP-1 solution and much lower than that of the F(P1) hydrogel. This results 
suggests that the initial burst release of GLP-1 was suppressed by the lower swelling of the gel resulting 
from covalent cross-linking, in good agreement with the in vitro results. Interestingly, although 
F(P1/D+PA40) hydrogel exhibited no detectable release of GLP-1 after 3 days in vitro, rats in the 
F(P1/D+PA40) group showed higher plasma GLP-1 levels (about 300 ng/L) between Day 7 and Day 25 
compared with the F(P1) and control rats. These results suggest that the hydrogel network in 
F(P1/D+PA40) might be partially hydrolyzed by body fluids or by autocatalytic effects24, resulting in the 
slow release of the GLP-1 entrapped in the hydrogel matrix in vivo. This speculation is supported by the 
results of a physical strength study (Table 3). The G' value of subcutaneously implanted F(P1/D+PA40) 
hydrogel was 1147 Pa after 25 days, which is much lower than the G' value obtained in vitro after 30 
days' incubation (4202 Pa), suggesting partial degradation. Kim et al. reported that the blood glucose 
level decreased significantly at a plasma GLP-1 level of around 200 ng/L25. Therefore, the plasma GLP-1 
level (about 300 ng/L) obtained following the injection of F(P1/D+PA40) hydrogel containing GLP-1 
should be sufficient to be pharmacologically active over a period of 25 days. Figure 9 shows photographs 
of the sites where the formulations were injected subcutaneously in rats 25 days. All F(P1) hydrogel 
injected disappeared within 25 days, whereas all F(P1/D+PA40) hydrogel remained at the injection site 
after 25 days and was in the gel state (G' (1147 Pa) was larger than G" (364 Pa); Table 3). We can, 
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therefore, expect the continuous release of GLP-1 from F(P1/D+PA40) hydrogel even after 25 days. 
 
 
Figure 8. (a) Active GLP-1 concentration in plasma after subcutaneous injection for 25 days. (b) The 
Magnification of the area between Day 6 and 25. GLP-1 solution (×), F(P1) containing 
GLP-1 (●), F(P1/D+PA40) containing GLP-1 (■), and F(P1/D+PA40) without GLP-1 (◆). 
The data are shown as the mean ± SE (n = 4-6). ＊: P < 0.05 vs F(P1) containing GLP-1. 
 
 
 
 
 
 
 
 
 
Figure 9. Photographs of hydrogels (a) F(P1), (b) F(P1/D+PA40) 25 days after subcutaneous injection 
in rats. The values indicate the number of rats harboring hydrogel/all rats. 
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3.4  Conclusions 
   We achieved long-term maintenance levels of plasma GLP-1 in vivo by using biodegradable IP 
system that shows irreversible gelation due to covalent bond formation. Compared with a conventional 
physical gelation system, this irreversible hydrogel system exhibits a lower swelling ratio early in the 
drug release process, a suppressed initial burst, and sustained release of the encapsulated drug. Moreover, 
the system remained in the gel state for a longer time and gradually degraded after subcutaneous 
injection, which could help maintain a therapeutic blood drug level for over 1 month. This IP formulation 
did not exhibit severe cytotoxicity. Therefore, this irreversible IP hydrogel system holds promise for use 
in a minimally invasive sustained drug release system for hydrophilic compounds such as peptides and 
proteins. Especially, the IP system with GLP-1 can be a new effective therapeutic system for type 2 
diabetes providing good quality of life of patients without frequent injections. 
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Chapter 4 
Concluding Remarks 
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   In Chapter 2, I investigated polymer chain transfer (exchange) between micelles composed of 
temperature-responsive biodegradable polymer through gelling process. Amphiphilic triblock copolymers 
of poly(ethylene glycol) (PEG) and aliphatic polyesters such as poly(ε-caprolactone-co-glycolide) (PCGA) 
are typical examples of thermo-gelling polymers. In the gelation mechanism of these polymers, polymer 
chain transfer between the micelles, and subsequent aggregation of the polymer micelles are important 
steps. We previously reported an IP system exhibiting a temperature-responsive irreversible sol-gel 
transition that formed a covalently cross-linked hydrogel. The IP formulation prepared by the "freeze-dry 
with PEG/dispersion" method (D-sample) retained its sol state at r.t. longer than a formulation prepared by 
the usual dissolution method (S-sample). I hypothesized that polymer chain transfer between micelles was 
suppressed in the D-samples, because the micelle cores were in a solid-like semi-crystalline state. In this 
study, I investigated polymer chain transfer by the fluorescence resonance energy transfer (FRET) method 
to reveal its role in the sol-to-gel transition. We synthesized a triblock copolymer of PCGA and PEG 
(tri-PCG) with covalently attached naphthalene or dansyl groups at both termini, tri-PCG-nap and 
tri-PCG-dan, as FRET donors and acceptors, respectively. The FRET behavior of the mixture of 
tri-PCG-nap/tri-PCG micelles and tri-PCG-dan/tri-PCG micelles was investigated. It was revealed that 
polymer chain transfer between micelles was strongly accelerated at the gelation temperature, and polymer 
chain transfer in D-samples was suppressed compared to S-samples. 
 
   In chapter 3, I investigated the release behavior of glucagon-like peptide-1 (GLP-1) from a 
biodegradable injectable polymer (IP) hydrogel. This hydrogel shows temperature-responsive irreversible 
gelation due to the covalent bond formation through a thiol-ene reaction. In vitro sustained release of 
GLP-1 from an irreversible IP formulation F(P1/D+PA40) was observed compared with a reversible 
(physical gelation) IP formulation (F(P1)). Moreover, pharmaceutically active levels of GLP-1 were 
maintained in blood after subcutaneous injection of the irreversible IP formulation into rats. This system 
should be useful for the minimally invasive sustained drug release of peptide drugs and other water-soluble 
bioactive reagents. 
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